CO2020004977A2 - Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa - Google Patents

Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa

Info

Publication number
CO2020004977A2
CO2020004977A2 CONC2020/0004977A CO2020004977A CO2020004977A2 CO 2020004977 A2 CO2020004977 A2 CO 2020004977A2 CO 2020004977 A CO2020004977 A CO 2020004977A CO 2020004977 A2 CO2020004977 A2 CO 2020004977A2
Authority
CO
Colombia
Prior art keywords
ripi
kinase inhibitors
bicyclic compounds
compounds
ring
Prior art date
Application number
CONC2020/0004977A
Other languages
English (en)
Inventor
Guiling Zhao
Craig Stivala
Blake Daniels
Huifen Chen
Gregory Hamilton
Snahel Patel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2020004977A2 publication Critical patent/CO2020004977A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La invención proporciona nuevos compuestos que presentan la fórmula general I: o sales farmacéuticamente aceptable de los mismos, en los que: RA, RB1, RB2, el anillo A y el anillo B son tal como se indica en la presente memoria, composiciones farmacéuticas que incluyen los compuestos y métodos de utilización de los compuestos como inhibidores de RIPI quinasa.
CONC2020/0004977A 2017-10-11 2020-04-23 Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa CO2020004977A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570892P 2017-10-11 2017-10-11
PCT/EP2018/077656 WO2019072942A1 (en) 2017-10-11 2018-10-10 BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1

Publications (1)

Publication Number Publication Date
CO2020004977A2 true CO2020004977A2 (es) 2020-05-05

Family

ID=63840848

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0004977A CO2020004977A2 (es) 2017-10-11 2020-04-23 Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa

Country Status (19)

Country Link
US (1) US11673892B2 (es)
EP (1) EP3694858B1 (es)
JP (1) JP7362600B2 (es)
KR (1) KR20200070297A (es)
CN (1) CN111201229A (es)
AU (1) AU2018348930A1 (es)
BR (1) BR112020007067A2 (es)
CA (1) CA3078653A1 (es)
CL (1) CL2020000944A1 (es)
CO (1) CO2020004977A2 (es)
CR (1) CR20200151A (es)
IL (1) IL273443A (es)
MA (1) MA50356A (es)
MX (1) MX2020003439A (es)
PE (1) PE20211246A1 (es)
PH (1) PH12020550253A1 (es)
RU (1) RU2020114670A (es)
SG (1) SG11202003283TA (es)
WO (1) WO2019072942A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
CA3185865A1 (en) 2017-07-14 2019-01-17 F. Hoffmann-La Roche Ag Bicyclic ketone compounds and methods of use thereof
PE20211247A1 (es) 2017-10-31 2021-07-13 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos
EP3908586B1 (en) * 2019-01-11 2022-12-21 F. Hoffmann-La Roche AG Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
WO2023039795A1 (zh) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Rip1激酶抑制剂及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
AU8405691A (en) * 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
WO1998056376A1 (en) 1997-06-13 1998-12-17 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
UA76461C2 (en) 2001-05-24 2006-08-15 Lilly Co Eli Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
MX2009008546A (es) 2007-02-07 2009-10-08 Pfizer Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldehido como inhibidores de la proteina quinasa c.
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
IN2014MN00258A (es) 2011-07-15 2015-09-25 Janssen Pharmaceuticals Inc
EP2852584B1 (en) 2012-05-22 2018-02-28 F. Hoffmann-La Roche AG Substituted dipyridylamines and uses thereof
BR112015016395A2 (pt) 2013-01-18 2017-07-11 Hoffmann La Roche pirazóis 3-substituídos e uso como inibidores de dlk
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
CN105164114B (zh) 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
CN110003178B (zh) 2013-05-01 2022-02-25 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2016142310A1 (en) 2015-03-09 2016-09-15 F. Hoffmann-La Roche Ag Tricyclic dlk inhibitors and uses thereof
NZ737297A (en) 2015-07-02 2024-03-22 Hoffmann La Roche Bicyclic lactams and methods of use thereof
EP3414239A2 (en) 2016-02-05 2018-12-19 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
CL2020000944A1 (es) 2020-08-21
EP3694858B1 (en) 2023-01-11
RU2020114670A (ru) 2021-11-12
KR20200070297A (ko) 2020-06-17
PH12020550253A1 (en) 2021-02-22
BR112020007067A2 (pt) 2020-10-06
CA3078653A1 (en) 2019-04-18
AU2018348930A1 (en) 2020-03-26
WO2019072942A1 (en) 2019-04-18
SG11202003283TA (en) 2020-05-28
CR20200151A (es) 2020-05-23
PE20211246A1 (es) 2021-07-13
JP7362600B2 (ja) 2023-10-17
EP3694858A1 (en) 2020-08-19
US11673892B2 (en) 2023-06-13
MA50356A (fr) 2021-04-21
IL273443A (en) 2020-05-31
MX2020003439A (es) 2020-07-29
CN111201229A (zh) 2020-05-26
JP2020536915A (ja) 2020-12-17
US20200283446A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
DOP2019000030A (es) Inhibidores de cdk2/4/6
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
ECSP16074478A (es) Compuestos novedosos
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
NI201900077A (es) Inhibidores selectivos de jak1
ECSP17069696A (es) Compuestos novedosos
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
ECSP18056196A (es) Derivados de indano